MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

Home・Akciju saraksts・AnaptysBio Inc

AnaptysBio Inc

Slēgts

SektorsVeselības aprūpe

67.86 -3.13

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

67.21

Max

70.01

Galvenie mērījumi
By Trading Economics
Ienākumi	35M 50M
Pārdošana	32M 108M
Peļņas marža	45.833
Darbinieki	104
EBITDA	29M 68M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+21.08% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	440M 2B
Iepriekšējā atvēršanas cena	70.99
Iepriekšējā slēgšanas cena	67.86

Ziņu noskaņojums

By Acuity

40%

60%

138 / 348 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bearish Evidence

19.25 / 21.135 Atbalsts un pretestība

AnaptysBio Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 14. apr. 23:36 UTC

Iegādes, apvienošanās, pārņemšana

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion -- Update

2026. g. 14. apr. 23:24 UTC

Karstas akcijas

Stocks to Watch: Gloo, Broadcom, GitLab

2026. g. 14. apr. 22:42 UTC

Iegādes, apvienošanās, pārņemšana

China-Backed Yancoal Australia to Buy Kestrel Coal Mine Stake For Up to $2.4 Billion

2026. g. 14. apr. 21:32 UTC

Galvenie tirgus virzītāji

GitLab Shares Rise on Expanded Google Cloud Collaboration

2026. g. 14. apr. 23:54 UTC

Tirgus saruna

Nikkei May Rise as Fears About Energy Shortage Ease -- Market Talk

2026. g. 14. apr. 23:34 UTC

Tirgus saruna

Gold Edges Lower on Possible Technical Correction -- Market Talk

2026. g. 14. apr. 22:54 UTC

Peļņas

BRP: Amendment Mainly Leads to 25% Tariff on Total Value of Imported Snowmobiles and Majority of ORV Models, Replacing Previous 50% Tariff on Applicable Metal Content Only >DOO.T

2026. g. 14. apr. 22:54 UTC

Peļņas

BRP: Suspending Guidance Following Amendment of Section 232 Tariffs on Steel, Aluminum and Copper Imports Into U.S., Which Came Into Effect on April 6 >DOO.T

2026. g. 14. apr. 22:54 UTC

Peļņas

BRP: Currently Estimates Potential Incremental Tariff Cost Related to This Amendment in Excess of $500M for Remainder of Yr >DOO.T

2026. g. 14. apr. 22:54 UTC

Peļņas

BRP: Suspends FY27 Guidance Due to Changes to U.S. Tariff Environment

2026. g. 14. apr. 22:17 UTC

Iegādes, apvienošanās, pārņemšana

Yancoal Australia: Targets Deal Completion Toward End of 3Q

2026. g. 14. apr. 22:17 UTC

Iegādes, apvienošanās, pārņemšana

Yancoal Australia: Acquisition Diversifies Portfolio; Met Coal Share to Rise to 22%

2026. g. 14. apr. 22:17 UTC

Iegādes, apvienošanās, pārņemšana

Yancoal Australia: Asset 'Strong Strategic Fit'; to Positively Add Production, Cash Flow

2026. g. 14. apr. 22:16 UTC

Iegādes, apvienošanās, pārņemšana

Yancoal Australia: Intends to Fund Acquisition With Cash, 5-Year Loan Facility

2026. g. 14. apr. 22:15 UTC

Iegādes, apvienošanās, pārņemšana

Yancoal Australia: Contingent Consideration Linked to Average Annual Prices For 5 Years

2026. g. 14. apr. 22:14 UTC

Iegādes, apvienošanās, pārņemšana

Yancoal Australia: Deal Includes Contingent Cash Consideration Up to $550 Million

2026. g. 14. apr. 22:13 UTC

Iegādes, apvienošanās, pārņemšana

Yancoal Australia: Deal Includes $1.85 Billion Upfront Consideration

2026. g. 14. apr. 22:12 UTC

Iegādes, apvienošanās, pārņemšana

Yancoal Australia: To Buy Kestrel Stake From EMR Capital, Adaro Capital

2026. g. 14. apr. 22:12 UTC

Iegādes, apvienošanās, pārņemšana

Yancoal Australia: To Buy Kestrel Stake For Up to $2.4 Billion

2026. g. 14. apr. 22:10 UTC

Iegādes, apvienošanās, pārņemšana

Yancoal Australia: to Acquire 80% Interest in Kestrel Coal Mine

2026. g. 14. apr. 20:50 UTC

Tirgus saruna

Iegādes, apvienošanās, pārņemšana

Basic Materials Roundup: Market Talk

2026. g. 14. apr. 20:33 UTC

Iegādes, apvienošanās, pārņemšana

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

2026. g. 14. apr. 20:32 UTC

Karstas akcijas

Stocks to Watch: JPMorgan, American Airlines, LVMH, BlackRock -- WSJ

2026. g. 14. apr. 19:59 UTC

Iegādes, apvienošanās, pārņemšana

Microsoft Is Buying 3,200 Acres For a Data Center. This Utility Stock Is Rising. -- Barrons.com

2026. g. 14. apr. 19:38 UTC

Peļņas

Johnson & Johnson Financial Chief Sees 'Clear Line of Sight' to Double-Digit Growth by 2030 -- Barrons.com

2026. g. 14. apr. 19:27 UTC

Tirgus saruna

U.S. Natural Gas Futures Extend Losing Streak -- Market Talk

2026. g. 14. apr. 19:21 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Retreat on Hopes for U.S.-Iran Peace Talks -- Market Talk

2026. g. 14. apr. 19:09 UTC

Iegādes, apvienošanās, pārņemšana

Apple and Amazon Partner on Satellite Deal. Why It Makes Sense. -- Barrons.com

2026. g. 14. apr. 18:30 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 14. apr. 18:30 UTC

Tirgus saruna

Treasury Yields, Dollar Fall as Markets Price Higher Odds of Fed Cuts -- Market Talk

Salīdzinājums

Cenas izmaiņa

AnaptysBio Inc Prognoze

Cenas mērķis

By TipRanks

21.08% augšup

Prognoze 12 mēnešiem

Vidējais 83.22 USD 21.08%

Augstākais 140 USD

Zemākais 50 USD

Pamatojoties uz 10 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AnaptysBio Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

10 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 10 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam AnaptysBio Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

19.25 / 21.135Atbalsts un pretestība

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

138 / 348 Rangs Veselības aprūpe

Finanšu rādītāji

Par AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.